Journal Basic Info
- Impact Factor: 1.995**
- H-Index: 8
- ISSN: 2474-1647
- DOI: 10.25107/2474-1647
Major Scope
- Minimally Invasive Surgery
- Vascular Surgery
- General Surgery
- Ophthalmic Surgery
- Thoracic Surgery
- Plastic Surgery
- Urology
- Orthopaedic Surgery
Abstract
Citation: Clin Surg. 2021;6(1):3279.Research Article | Open Access
Cyclobenzaprine as a Medication to Manage Pain and Improve Sleep Quality in Patients with Myofascial Pain: A Systematic Review and Meta-Analysis
Luciana Uemoto1*, Rizomar Ramos do Nascimento1, Danielle Masterson2, Claudia Trindade Mattos1, Francisco Guedes Pereira de Alencar3 and Oswaldo de Vasconcellos Vilella1
1Department of Orthodontics, Federal Fluminense University, Niterói, Rio de Janeiro, Brazil
2Library of the Federal University of Rio de Janeiro, Rio de Janeiro, Brazil
3Department of Prosthodontics, University of Santo Amaro, São Paulo, Brazil
*Correspondance to: Luciana Uemoto
PDF Full Text DOI: 10.25107/2474-1647.3279
Abstract
Purposes: To assess the efficacy of cyclobenzaprine in the management of pain intensity and sleep quality in patients diagnosed with orofacial myofascial pain. Methods: PubMed, Scopus, Web of Science, the Cochrane Library, LILACS, BBO and Embase was searched based on the guidelines for each database, and it was updated until July 2021. Randomized clinical trials, cohort studies, and case-control studies evaluating the use of cyclobenzaprine in the management of myofascial pain were included, with a minimal follow up of three weeks. Two authors carried out data extraction from the studies, and the risk of bias was assessed according to the Cochrane Collaboration's tool for assessing the risk of bias in randomized clinical trials. Results: One hundred and seventy two studies were identified, whereby only three studies met the inclusion criteria. After a sensitive analysis, two studies comprising 86 participants were selected for the meta-analysis. The primary outcome was the change in pain intensity between initial and final measurements, which was significantly higher for the cyclobenzaprine group (95% CI, 0.027 to 0.283). A secondary outcome was the change in sleep quality between pre- and post-treatment that showed higher statistical significance for the cyclobenzaprine group (95% CI, 0.618 to 2.05). The risk of bias was considered low for five of six domains. Blinding in the management phase was considered unclear, and the small number of participants generated imprecision. Conclusion: Evidence supports the effectiveness of cyclobenzaprine in the management of myofascial pain in short-terms, resulting in an improvement in pain and sleep quality.
Keywords
Cite the article
Uemoto L, Ramos do Nascimento R, Masterson D, Trindade Mattos C, de Alencar FGP, de Vasconcellos Vilella O. Cyclobenzaprine as a Medication to Manage Pain and Improve Sleep Quality in Patients with Myofascial Pain: A Systematic Review and Meta- Analysis. Clin Surg. 2021; 6: 3279..